Today, we honor the legacy of Dr. Martin Luther King Jr., a leader whose courage, vision, and unwavering commitment to justice and equality continue to inspire us. Let us reflect on his powerful message of unity and work together to build a brighter, more equitable future for all

Happy Thanksgiving! We’re grateful for our amazing team, patients, and partners who make everything we do possible. Wishing you and your loved ones a joyful and peaceful holiday!

Humanitarian efforts often go unnoticed, especially in outreach programs. In this video, hear firsthand from two of our incredible Outreach Specialists, Edgar Lizarraga and Alejandra Castro Beltran, as they share what their roles mean to them.

Dr. Naim Alkhouri will be presenting on “Treatment of MetALD: Challenges and Opportunities” during the panel on Metabolic Dysfunction-Associated and Alcohol-Associated Liver Disease (MetALD) at #AASLD #TheLiverMeeting Location: Convention Center: Room 24 When: Nov 18, 4:10-4:20

Join us at #AASLD’s The Liver Meeting! 🩺 Dr. Naim Alkhouri will present Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient. 📅 Sun, Nov 17 | ⏰ 12:30 PM - 2 PM 📍 Ballroom 20A Don’t miss insights on early ID, treatment, & long-term care! #LiverHealth

We’re thrilled to spotlight Dylan Moore, Director of VEN Centers, presenting at The Liver Meeting 2024! Topic: Advanced Practice Providers in HCV & MASLD – Rapid Start-Up of a Field-Based Hepatitis C Elimination Program When: Nov. 17, 2024, 5:00–5:15 PM Where: Ballroom 6F

A packed house tonight for the CME symposium: “The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care,” featuring Drs. Naim Alkhouri, Amreen Dinani, & Nicholas Pennings. Supported by grants from Boehringer Ingelheim & Novo Nordisk. #CME

Dylan Moore will participate in the panel “Hepatology Associates as Leaders in HCV Elimination Programs,” discussing the crucial roles of advanced providers, nurses, and pharmacists in HCV care and strategies for overcoming treatment barriers.

Arizona Liver Health/Arizona Clinical Trials is excited to attend #AASLD #TheLiverMeeting2024 in San Diego this weekend! We're dedicated to learning, collaboration, and advancing patient care through the latest in liver health. DM us or comment below to connect with our team!

We’re excited to announce Five Abstracts by presenting author: Dr. Naim Alkhouri of Arizona Liver Health at AASLD's The Liver Meeting 2024!

Dylan Moore from VEN Centers joins INHSU 2024 (San Diego) for Sessions 2 & 4 on Hepatitis C care! Highlights include roundtable discussions with hands-on stations led by experts on HCV testing, linkage to care, and treatment.

Join ALH at #AASLD’s 75th Liver Meeting, Nov 15-19 at the SD Convention Center! Connect with our experts @AlkhouriNaim @anitakohli Dr. Richard Manch, @ann_MooreNP, Angie Coste, and Dylan Moore. To schedule a meeting, contact Michelle at mjones@azliver.com or +1 303-406-1735

Today, we honor those who served with courage and commitment. Thank you to all veterans for the sacrifices you've made to protect our freedom. #VeteransDay #ThankYouVeterans

Meet us at The 75th Liver Meeting by AASLD to discuss partnership opportunities at our ACT Phase 1 Unit! With rapid start-up, advanced data collection, and a strong participant network, we're ready to support trials in hepatic impairment, PK/PD, and more. See you there!

Wrapping up a successful @IDWeekmtg! If we didn’t get a chance to meet-please contact Michelle at mjones@azclinicaltrials.com or +1 303-406-1735.

Honored to partner with The Mexican Consulate, an organization that provides vital resources, emergency assistance and unites the community. Together, we offered free Hep C testing and fibroscans to the community.

Early detection is crucial in liver disease. At ALH, we provide advanced, non-invasive diagnostics to catch conditions like MASLD, hepatitis, and liver cancer early. Encourage your patients to get screened. Submit referrals:

Dr. Anita Kohli & Michelle Jones will be at IDWeek on Oct 18-19! Let's connect to discuss our Phase 1 & 2-4 trial capabilities, including 24 dedicated Phase 1 beds, USP 800 research pharmacy, telemetry monitoring, and more. Contact mjones@azclinicaltrials.com or +1 303-406-1735

@anitakohli & @mjonescov will be at IDWeek on Oct 18-19! Let's connect and meet to discuss our Phase 1 & 2-4 trial capabilities, including 24 dedicated Phase 1 beds, USP 800 research pharmacy, telemetry monitoring, and more. Contact mjones@azclinicaltrials.com or +1 303-406-1735

Last week, Brennin Palfrey of VEN Centers presented data on HCV disparities in underserved AZ communities. Among 3,168 tested, infection rates were high in unsheltered (16.88%), people who use drugs (8.83%), and previously incarcerated (11.92%). VEN’s mobile care model is key.